NCT04141644View on ClinicalTrials.gov

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 20, 2020

Primary Completion Date

January 29, 2024

Study Completion Date

April 30, 2028

Conditions
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
Interventions
DRUG

Ipilimumab

Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks

DRUG

Osimertinib

Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER